Beware of ‘intergalactic committees'—small, focused teams are the best way to get work done
You've been on an intergalactic committee before—you just didn't know what to call it. An intergalactic committee looks like a meeting or 'task force' with dozens of people—multiples of delegates from each function of a big organization who are brought in to represent small distinctions relating to their discipline. While a few participants meaningfully contribute, tangential ideas seem to suck all the oxygen out of the room, hampering efforts to address the important challenge at hand.
How does an intergalactic committee form? The forward button on a meeting invite. The idea that there's a correlation between the priority of a project, the titles of those involved, and the number of people enlisted. The well-meaning premise that one's colleague might not be able to bring every detail we possess, or that everyone needs to be on the committee to stay in the loop.
I remember years ago when we were building a new product within AT&T. We used the code name Project Zig, initially because the product was meant to be disruptive—we'll zig when they think we're going to zag. We held a kick-off meeting where two members from the project team walked through the highlights. More than 50 people from all areas of the business joined the meeting, driven largely by FOMO (fear of missing out). While we appreciated the interest, the sheer volume and types of niche questions were not productive.
When my small, dedicated Zig working group peeled away, it felt like we were flying—and 'zig' came to represent the speed and productivity we experienced with the smaller squad.
Jeff Bezos has the two-pizza rule, which can be further simplified to a one-pizza rule: Keep the group small enough that everyone gets a slice. Eight attendees or less. Small teams encourage equal participation, and the heightened transparency leads people to be more selfless in their contributions. It's hard to hide self-serving motives or organizational territorialism in a small circle. Each department should have only one empowered representative. Team members should be chosen based on alignment with the mission, not only their job title. Once the specialized delegates are in the room, they should have a broad remit and equal latitude to ensure that truly new approaches are fair game.
A clear leader is essential to harnessing the collective brain power of a group. While everyone gets a voice, not everyone should have a vote. There should be only one decision-maker, singularly focused on bringing the outcome back to the mission. That individual needs to consider all inputs and clearly articulate the decision and path forward. The team should engage in healthy, respectful debates, but all team members must be supportive once the direction is set. Clear communication on why a decision was made, and what is expected as a result, is critical to ensure alignment and speed of action across a broader organization.
We should steer clear of intergalactic committees as we tackle challenges, assemble teams, strive for swift impact, and evolve as leaders.
Of course, the essence of a high-performing team transcends merely avoiding pitfalls; it is fundamentally about envisioning and reaching our desired objectives. The key lies in establishing clear priorities that align with the mission and empowering team members who are accountable for delivering on that mission. When we unleash a small, empowered team to address our most formidable challenges, we pave the way for remarkable achievements.
The opinions expressed in Fortune.com commentary pieces are solely the views of their authors and do not necessarily reflect the opinions and beliefs of Fortune.
Read more:
Jeff Bezos reveals his formula for running the perfect meetings to weed out those 'who pretend to have done the reading'
Jack Dorsey tells Block employees Tuesday is a 'no meeting day.' Here's why that lifts the spirits of 'makers'
Nvidia CEO Jensen Huang has a no one-on-one meetings rule for his 55 direct reports
Meetings are a productivity killer—and 3 in every 4 are totally ineffective, according to a new wide-ranging study
This story was originally featured on Fortune.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Jeff Bezos' Blue Origin prepares for next human flight: Where to watch launch in Texas
Six more space tourists are preparing to join the growing ranks of civilians who have flown on a Blue Origin rocket to the edge of space. The vehicle they'll ride to orbit, Blue Origin's New Shepard, is the same one that 58 others have ridden to space on 11 previous human spaceflights from the company's west Texas facility. The New Shepard's maiden voyage in July 2021 with a crew even included billionaire Amazon founder Jeff Bezos, who also owns the space technology company. New Shepard is composed of both a rocket and a crew capsule, which is outfitted with large windows for its passengers to glimpse spectacular views that most of us will never see. The rest of us will instead have to content ourselves with watching the mission on solid ground. Fortunately, a town just south of the launch site may provide a few public places to catch the launch and spaceflight. Here's everything to know about Blue Origin's next human spaceflight and how to potentially see it in person. When is the next Blue Origin launch? What to know about New Shepard liftoff, crew Billionaire Jeff Bezos, best known for founding Amazon, is the founder of the private space technology company Blue Origin. Bezos himself even boarded Blue Origin's New Shepard for its maiden crewed voyage in July 2021, which came after the spacecraft flew on 15 flight tests beginning in 2012. For nearly four years since its first crewed mission, the New Shepard spacecraft has served as a powerful symbol of Blue Origin's commercial spaceflight ambitions amid a growing space tourism industry. In addition to sending space tourists on brief joy rides to the edge of space, Blue Origin has also increasingly sought to compete with Elon Musk's SpaceX. Blue Origin's massive New Glenn rocket, which flew on its inaugural flight test in January, is also being developed for future spaceflights. At 320 feet tall, the spacecraft rivals SpaceX's 400-foot Starship in size. Blue Origin's next crewed launch, known as NS-32, could get off the ground as early as 8:30 a.m. CT (9:30 a.m. ET) Saturday, May 31, the company announced announced Tuesday, May 27. Blue Origin New Shepard rocket launches take place from the company's private ranch facility known as Launch Site One. The facility is located 30 miles north of the town of Van Horn in Culberson County – more than 140 miles east of El Paso near the U.S.-Mexico border. Blue Origin does not provide any public viewing areas for launches at or near its facility, which is located in a remote desert. Van Horn, the nearest town, is too far away to see the launch pad itself, but is likely the best place to see a New Shepard rocket soar into the sky. The town's visitors bureau advertises Blue Origin on its homepage and its brochure as an attraction, but does not list any public viewing locations for launches. The USA TODAY Network left a message Thursday, May 29 with the visitor's bureau seeking more information. In the meantime, here is a list of public places in and around Van Horn listed as attractions on the visitors' bureau website where spectators might be able to see a rocket taking off: Van Horn city park, 3rd and Austin Streets Okey D. Lucas Memorial Park, 1804 W. Broadway St., Van Horn Guadalupe Mountains National Park, located about 60 miles north of Van Horn in Dell City and 40 miles north of the launch site, the park bordering New Mexico has the highest point in Texas. Here's a look at the passengers on the next Blue Origin spaceflight: Aymette (Amy) Medina Jorge, a STEM teacher at Odyssey Academy in Galveston, Texas, who has led more than 60 zero-gravity space experiments. Gretchen Green, a radiologist specializing in women's imaging with more than 20 years of clinical experience. Jaime Alemán, a Panamanian attorney, businessman and former ambassador to the United States. Jesse Williams, a Canadian entrepreneur and adventurer who serves as CEO of Car History Group, which he founded in 2012. Mark Rocket, an entrepreneur from Christchurch, New Zealand, who is CEO of Kea Aerospace, which develops solar-powered UAVs for aerial imaging and monitoring, and president of Aerospace New Zealand. Paul Jeris, a real estate developer and entrepreneur Each spaceflight on a New Shepard vehicle lasts about 11 minutes from liftoff to capsule touchdown. Named after astronaut Alan Shepard, the first American in space, the 60-foot-tall New Shepard rocket is topped with the gum drop-shaped crew capsule. During its ascent, the spacecraft reaches supersonic speeds surpassing 2,000 mph before the rocket booster separates from the crew capsule. At that point, those aboard the capsule become weightless as the spacecraft continues toward its highest point on its brief voyage above the Kármán Line – the 62-mile-high internationally recognized boundary of space. While experiencing a few minutes of microgravity, passengers have the opportunity to unstrap themselves from their seats to gaze out the capsule's large windows and take in a stunning view of Earth. Meanwhile, the rocket booster heads back to the ground while firing its engines and using its fins to slow and control its descent to land vertical about two miles from the launchpad. The capsule itself eventually begins what Blue Origin refers to as a "stable freefall' – plummeting back to Earth as three massive parachutes deploy and the capsule makes a soft landing in the desert, sending up plumes of dust. Eric Lagatta is the Space Connect reporter for the USA TODAY Network. Reach him at elagatta@ This article originally appeared on El Paso Times: Is there a Blue Origin launch today? Where to see liftoff from Texas
Yahoo
6 hours ago
- Yahoo
When is the next Blue Origin crewed launch from Texas? What to know about New Shepard
A new group of people are about to join more than 60 others who have previously boarded a Blue Origin spacecraft for a brief voyage treating them to stunning views of Earth few have seen. Blue Origin, the commercial spaceflight company founded by billionaire Jeff Bezos, is preparing to send six more people to the edge of space as early as Saturday, June 21. The impending launch would come just three weeks since the company's last human spaceflight from its private facilities in West Texas. Blue Origin also made headlines in March for a highly-publicized launch featuring an all-woman crew that included pop star Katy Perry and broadcast journalist Gayle King. The six people selected for the upcoming mission, known as NS-33, would join a growing list of celebrities and influential civilians who have had the rare privilege of serving as passengers on the company's New Shepard spacecraft. During a trip that lasts a matter of minutes, the New Shepard takes its passengers more than 60 miles high to experience weightlessness and spectacular views of Earth. Here's everything to know about the upcoming mission, which would be New Shepard's 13th human spaceflight and 33rd overall. Billionaire Jeff Bezos, best known for founding Amazon, is the founder of the private space technology company Blue Origin. Bezos himself even boarded Blue Origin's New Shepard for its maiden crewed voyage in July 2021, which came after the spacecraft flew on 15 flight tests beginning in 2012. For nearly four years since its first crewed mission, the New Shepard spacecraft has served as a powerful symbol of Blue Origin's commercial spaceflight ambitions amid a growing space tourism industry. In addition to sending space tourists on brief joy rides to the edge of space, Blue Origin has also increasingly sought to compete with Elon Musk's SpaceX. Blue Origin's massive New Glenn rocket, which flew on its inaugural flight test in January, is also being developed for future spaceflights. At 320 feet tall, the spacecraft rivals SpaceX's 400-foot Starship in size. Even Amazon is competing with SpaceX by developing its own Kuiper internet satellite constellation in a direct challenge to Starlink. Blue Origin's next crewed launch, known as NS-33, could get off the ground as early as 8:30 a.m. CT (9:30 a.m. ET) Saturday, June 21, the company announced Tuesday, June 17. Blue Origin New Shepard rocket launches take place from the company's private ranch facility known as Launch Site One. The facility is located 30 miles north of the town of Van Horn in Culberson County – more than 140 miles east of El Paso near the U.S.-Mexico border. The passengers on the next mission, whose names Blue Origin announced Friday, June 13, are a group mostly conservationists and business leaders. When the New Shepard gets off the ground again, the six people selected to board it will join 64 others who have flown on the spacecraft across 12 previous human spaceflights. Here's a look at the passengers: Allie Kuehner, an environmentalist who serves on the board of Nature is Nonpartisan, a nonprofit organization advocating for bipartisan solutions to environmental issues Carl Kuehner, who chairs Building and Land Technology, a real estate development, investment and property management firm Leland Larson, a philanthropist and former CEO of School Bus Services and Larson Transportation Services – both family-owned public transportation businesses based in Oregon Freddie Rescigno, Jr., CEO of Commodity Cables, an electrical company he founded in 2001 Owolabi Salis, an attorney and a financial consultant Jim Sitkin, a retired lawyer from California Each spaceflight on a New Shepard vehicle lasts about 11 minutes from liftoff to capsule touchdown. Named after astronaut Alan Shepard, the first American in space, the 60-foot-tall New Shepard rocket is topped with the gum drop-shaped crew capsule. The spacecraft operates completely autonomously, meaning no pilots are aboard. During its ascent, the spacecraft reaches supersonic speeds surpassing 2,000 mph before the rocket booster separates from the crew capsule. At that point, those aboard the capsule become weightless as the spacecraft continues toward its highest point on its brief voyage above the Kármán Line – the 62-mile-high internationally recognized boundary of space. While experiencing a few minutes of microgravity, passengers have the opportunity to unstrap themselves from their seats to gaze out the capsule's large windows and take in a stunning view of Earth. Meanwhile, the rocket booster heads back to the ground while firing its engines and using its fins to slow and control its descent to land about two miles from the launchpad. The capsule itself eventually begins what Blue Origin refers to as a "stable freefall' – plummeting back to Earth as three massive parachutes deploy and the capsule makes a soft landing in the desert, sending up plumes of dust. If you have dreams of blasting off to orbit on a Blue Origin spacecraft, you likely need to either have very deep pockets or a name that's recognizable enough to get you invited as an honored guest. Though Blue Origin does not publicly list prices on its website, a form to reserve a seat requires customers to agree to a $150,000 deposit alone. And if the price of the first ticket sold for a Blue Origin spaceflight in 2021 is any indicator, seats likely cost in the millions of dollars. The $28 million ticket price was the winning bid in an auction that included 7,600 people registered to bid from 159 countries. However, a select few passengers over the years have had their seats aboard New Shepard paid through grants and other funding methods from large institutions. Eric Lagatta is the Space Connect reporter for the USA TODAY Network. Reach him at elagatta@ This article originally appeared on El Paso Times: When is Blue Origin's next mission from Texas? Crew, liftoff, launch
Medscape
a day ago
- Medscape
Integrating CAR T and Bispecific Antibodies in MM Treatment
MILAN — The treatment landscape for relapsed and refractory multiple myeloma (RRMM) has shifted dramatically with the emergence of immunotherapies such as chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies (bsAbs). These novel approaches have delivered unprecedented outcomes in heavily pretreated patients. Yet determining the optimal treatment strategy remains a clinical challenge. Here at the 2025 European Hematology Association (EHA) Annual Meeting in Milan, Italy, leading experts weighed the strengths and limitations of both approaches, emphasizing that it is not a contest of superiority but a question of sequence and patient selection. Bispecific Antibodies: Off-the-Shelf Convenience With Strong Responses BsAbs work by redirecting T cells toward myeloma cells, binding simultaneously to a tumor antigen and CD3. In his presentation, Philippe Moreau, MD, head of the hematology department at the University Hospital of Nantes, France, reviewed the four agents approved in Europe: teclistamab, elranatamab, and linvoseltamab, which target beta cell maturation antigen (BCMA); and talquetamab, which targets G protein-coupled receptor class C group 5 member D (GPRC5D). These agents deliver overall response rates (ORRs) of 60%-70% in heavily pretreated patients, with median progression-free survival (PFS) of 12-18 months and overall survival (OS) of 24-30 months. Talquetamab in particular induces rapid responses within 1 month but is associated with unique toxicities — such as skin reactions, dysgeusia, and mucosal effects — related to GPRC5D expression in nonhematopoietic tissues like skin. BsAbs offer immediate treatment without the delays associated with CAR T manufacturing. They are also viable for frail patients and more broadly accessible outside of specialized centers. Toxicities, including cytokine release syndrome and infections, are generally manageable with step-up dosing and prophylactic tocilizumab. However, resistance remains a main concern. Roughly one third of patients — particularly those with high-risk cytogenetics, International Staging System stage III disease, or extramedullary disease — exhibit primary resistance. CAR T-Cell Therapy: Durable Outcomes With Earlier Use CAR T-cell therapies have redefined expectations in RRMM, particularly with ciltacabtagene autoleucel, which has achieved a median PFS of 35 months and a median OS approaching 61 months in heavily pretreated populations. Notably, recent data show that one third of patients remain progression-free at 5 years: an unprecedented milestone. 'Phase 3 trials now show improved PFS, OS, and quality of life compared to standard-of-care regimens,' said Paula Rodriguez-Otero, MD, medical coordinator of the Central Unit for Clinical Trials at the University of Navarra, Pamplona, Spain. However, CAR T therapy faces logistical hurdles, including manufacturing delays and the need for specialized infrastructure. High-risk patients with rapid progression or poor bridging therapy responses may still experience suboptimal results, but these challenges are mitigated when CAR T therapy is used earlier in the disease course, before T-cell exhaustion occurs. It's Not One or the Other Both speakers agreed that the future of MM treatment is not about choosing between CAR T and bsAbs but about defining the optimal sequence and integrating both modalities based on patient needs and disease features. BsAbs offer fast, outpatient-ready options for frail or rapidly progressing patients. CAR T therapies, though more complex, offer long remissions and potential treatment-free intervals, especially when used early. Still, Moreau cautioned, many questions remain. What is the best treatment sequence? Should clinicians switch targets — for example from BCMA to GPRC5D — or stick with the same? How should resistance mechanisms, such as antigen loss, be tackled? Can we move toward fixed-duration therapy to reduce costs? Scientific progress must also account for patient priorities. As Solène Clavreul, PhD, noted in an interview with Medscape Medical News , longer survival for myeloma patients means that quality of life is increasingly central. Clavreul is patient advocate and head of medical education and scientific engagement at Myeloma Patients Europe. 'The treatment choices should always be based on research data, but understanding patients' preferences is critical for shared decision-making,' she said. What's Next: BsAb Combinations and Trispecifics 'With 19 new drugs or combinations approved in the past two decades, we've made incredible progress,' said Jesús San Miguel Izquierdo, MD, PhD, director of clinical and translational medicine at the University of Navarra, Pamplona, Spain, in his EHA 2025 Lifetime Achievement Award lecture. Two industry-sponsored studies presented at EHA 2025 point to the next wave of innovation. RedirecTT-1: Dual-Antigen BsAb Combination The phase 2 RedirecTT-1 trial evaluated the combination of talquetamab and teclistamab in patients with extramedullary disease. 'Patients with true extramedullary disease are up to 87% less likely to respond to conventional therapy,' said Shaji Kumar, MD, consultant, professor, and researcher at the Mayo Clinic, Rochester, USA. The combination treatment in the trial yielded an ORR of 78.9% and a complete response rate of 54.4%, with a 12-month PFS rate of 61% and OS rate of 74.5%. Adverse events were not significantly higher than in monotherapy trials, and less frequent dosing (biweekly or monthly) improved tolerability. 'These results showed deep and durable responses in a population with a significant unmet need,' Kumar said. Moreau, who was not involved in the study, added, 'This could be the pivotal trial that leads to approval of the first bsAb combination.' JNJ-5322: First-in-Human Trispecific Antibody JNJ-5322, a trispecific antibody targeting both BCMA and GPRC5D, showed remarkable efficacy in BCMA/GPRC5D-naive patients in a phase 1 trial. 'Despite recent progress, we still need to reduce treatment burden and improve outcomes,' said Rakesh Popat, MD, hematologist at University College Hospital, London, UK. Among patients with triple-class exposed RRMM, the ORR was 100%, with a 70.4% complete response rate and 12-month PFS of 95%. Grade 3/4 infections occurred in 28.6% of patients, but the safety profile — including mild cytokine release syndrome — was manageable. 'JNJ-5322 demonstrated manageable safety and an ORR comparable to CAR T, with convenient, off-the-shelf, weekly dosing, with one step-up dosing to facilitate outpatient dosing,' Popat concluded. Popat, Clavreul, and Kumar reported no relevant financial relationships. Moreaureported honoraria from and advisory board memberships with Janssen, Celgene, Takeda, Amgen, AbbVie, Sanofi, Pfizer, and GSK. Rodriguez Otero reported honoraria from lectures from BMS-Celgene, J&J Innovative Medicines, Sanofi, GSK, Regeneron, and Pfizer; participation in Ad Board meetings for BMS, Janssen, Sanofi, Oncopeptides, Pfizer, Roche, Regeneron, AbbVie, AstraZeneca, H3 Biomedicine, and GSK; consultancy work for BMS-Celgene, AbbVie, Roche, J&J Innovative Medicines, and Pfizer; and research funding and travel support from Pfizer. San Miguel Izquierdo reported participation on advisory boards and consulting services, on behalf of his institution, for AbbVie, Amgen, BMS, Celgene, GSK, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Pfizer, Takeda, Regeneron, Roche, Sanofi, Secura Bio, and Gilead-Kite. The two industry-sponsored studies mentioned were funded by Johnson & Johnson.
